Evidence map›Paper›PMID 38150231›Full record

ArticleJAMA cardiology2024

Variants at the Interleukin 1 Gene Locus and Pericarditis.

Rosa B Thorolfsdottir, Andrea B Jonsdottir, Gardar Sveinbjornsson, Hildur M Aegisdottir, Asmundur Oddsson, Olafur A Stefansson, Gisli H Halldorsson, Saedis Saevarsdottir, Gudmar Thorleifsson, Lilja Stefansdottir and 37 more

Open access · greenAbstract read
In one paragraph

Article in JAMA cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Review
  5. Review
  6. Review
  7. AFrontiers in immunology · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

47 authors at 13 institutions in 3 countries.

Rosa B ThorolfsdottirdeCODE genetics, Amgen, Reykjavik, Iceland.
Andrea B JonsdottirdeCODE genetics, Amgen, Reykjavik, Iceland.
Gardar SveinbjornssondeCODE genetics, Amgen, Reykjavik, Iceland.
Hildur M AegisdottirdeCODE genetics, Amgen, Reykjavik, Iceland.
Asmundur OddssondeCODE genetics, Amgen, Reykjavik, Iceland.
Olafur A StefanssondeCODE genetics, Amgen, Reykjavik, Iceland.
Gisli H HalldorssondeCODE genetics, Amgen, Reykjavik, Iceland.
Saedis SaevarsdottirdeCODE genetics, Amgen, Reykjavik, Iceland.
Gudmar ThorleifssondeCODE genetics, Amgen, Reykjavik, Iceland.
Lilja StefansdottirdeCODE genetics, Amgen, Reykjavik, Iceland.
Ole B PedersenDepartment of Clinical Immunology, Zealand University Hospital, Køge, Denmark.
Erik SørensenDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Jonas GhouseDepartment of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Anna Axelsson RajaDepartment of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Chaoqun ZhengDepartment of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Elvira SilajdzijaDepartment of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Søren Albertsen RandDepartment of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Christian ErikstrupDepartment of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
Henrik UllumStatens Serum Institut, Copenhagen, Denmark.
Christina MikkelsenDepartment of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Karina BanasikDepartment of Obstetrics and Gynaecology, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
Søren BrunakNovo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Erna V IvarsdottirdeCODE genetics, Amgen, Reykjavik, Iceland.
Asgeir SigurdssondeCODE genetics, Amgen, Reykjavik, Iceland.
Doruk BeyterdeCODE genetics, Amgen, Reykjavik, Iceland.
Arni SturlusondeCODE genetics, Amgen, Reykjavik, Iceland.
Hafsteinn EinarssondeCODE genetics, Amgen, Reykjavik, Iceland.
Vinicius TragantedeCODE genetics, Amgen, Reykjavik, Iceland.
Hannes HelgasondeCODE genetics, Amgen, Reykjavik, Iceland.
Sigrun H LunddeCODE genetics, Amgen, Reykjavik, Iceland.
Bjarni V HalldorssondeCODE genetics, Amgen, Reykjavik, Iceland.
Brynja D SigurpalsdottirdeCODE genetics, Amgen, Reykjavik, Iceland.
Isleifur OlafssonDepartment of Clinical Biochemistry, Landspitali, National University Hospital of Iceland, Reykjavik, Iceland.
David O ArnardeCODE genetics, Amgen, Reykjavik, Iceland.
Gudmundur ThorgeirssondeCODE genetics, Amgen, Reykjavik, Iceland.
Kirk U KnowltonIntermountain Medical Center, Intermountain Heart Institute, Salt Lake City, Utah.
Lincoln D NadauldPrecision Genomics, Intermountain Healthcare, Saint George, Utah.
Solveig GretarsdottirdeCODE genetics, Amgen, Reykjavik, Iceland.
Anna HelgadottirdeCODE genetics, Amgen, Reykjavik, Iceland.
Sisse R OstrowskiDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Daniel F GudbjartsssondeCODE genetics, Amgen, Reykjavik, Iceland.
Ingileif JonsdottirdeCODE genetics, Amgen, Reykjavik, Iceland.
Henning BundgaardDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Hilma HolmdeCODE genetics, Amgen, Reykjavik, Iceland.
Patrick SulemdeCODE genetics, Amgen, Reykjavik, Iceland.
Kari StefanssondeCODE genetics, Amgen, Reykjavik, Iceland.
Danish Blood Donor Study Genomic Consortium
deCODE Genetics (Iceland) · ISCopenhagen University Hospital · DKUniversity of Iceland · ISRigshospitalet · DKNational University Hospital of Iceland · ISUniversity of Copenhagen · DKAarhus University Hospital · DKNovo Nordisk Foundation · DKStatens Serum Institut · DKZealand University Hospital Køge · DKIntermountain Healthcare · USReykjavík University · ISUniversity of Utah · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Recurrent pericarditis is a treatment challenge and often a debilitating condition. Drugs inhibiting interleukin 1 cytokines are a promising new treatment option, but their use is based on scarce biological evidence and clinical trials of modest sizes, and the contributions of innate and adaptive immune processes to the pathophysiology are incompletely understood. Objective: To use human genomics, transcriptomics, and proteomics to shed light on the pathogenesis of pericarditis. Design, Setting, and Participants: This was a meta-analysis of genome-wide association studies of pericarditis from 5 countries. Associations were examined between the pericarditis-associated variants and pericarditis subtypes (including recurrent pericarditis) and secondary phenotypes. To explore mechanisms, associations with messenger RNA expression (cis-eQTL), plasma protein levels (pQTL), and CpG methylation of DNA (ASM-QTL) were assessed. Data from Iceland (deCODE genetics, 1983-2020), Denmark (Copenhagen Hospital Biobank/Danish Blood Donor Study, 1977-2022), the UK (UK Biobank, 1953-2021), the US (Intermountain, 1996-2022), and Finland (FinnGen, 1970-2022) were included. Data were analyzed from September 2022 to August 2023. Exposure: Genotype. Main Outcomes and Measures: Pericarditis. Results: In this genome-wide association study of 4894 individuals with pericarditis (mean [SD] age at diagnosis, 51.4 [17.9] years, 2734 [67.6%] male, excluding the FinnGen cohort), associations were identified with 2 independent common intergenic variants at the interleukin 1 locus on chromosome 2q14. The lead variant was rs12992780 (T) (effect allele frequency [EAF], 31%-40%; odds ratio [OR], 0.83; 95% CI, 0.79-0.87; P = 6.67 × 10-16), downstream of IL1B and the secondary variant rs7575402 (A or T) (EAF, 45%-55%; adjusted OR, 0.89; 95% CI, 0.85-0.93; adjusted P = 9.6 × 10-8). The lead variant rs12992780 had a smaller odds ratio for recurrent pericarditis (0.76) than the acute form (0.86) (P for heterogeneity = .03) and rs7575402 was associated with CpG methylation overlapping binding sites of 4 transcription factors known to regulate interleukin 1 production: PU.1 (encoded by SPI1), STAT1, STAT3, and CCAAT/enhancer-binding protein β (encoded by CEBPB). Conclusions and Relevance: This study found an association between pericarditis and 2 independent sequence variants at the interleukin 1 gene locus. This finding has the potential to contribute to development of more targeted and personalized therapy of pericarditis with interleukin 1-blocking drugs.

Indexed as

Genome-Wide Association StudyAdolescentFemaleFinlandGene FrequencyGenotypeHumansMalePhenotype

Identifiers

PMID38150231
PMCPMC10753444
OpenAlexW4390275334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.